Statins Inhibit Cytokines in a Dose-Dependent Response in Patients with Systemic Sclerosis
- 42 Downloads
Although statins have been successfully administered in the treatment of hypercholesterolemia and cardiovascular disease due to their lipid-lowering and anti-atherosclerotic action, they have shown immunomodulatory effects in several studies with immune-mediated diseases. The aim of this study was to investigate the effects of statins treatment on Th1, Th2, and Th17 cytokines production from stimulated peripheral blood mononuclear cells (PBMCs) obtained from Systemic Sclerosis (SSc) patients. We recruited 21 patients classified according to the American College of Rheumatology criteria for SSc for PBMCs culture analysis. Cytokine levels (IL-2, IL-4, IL-6, IL-10, TNF, IFN-γ, IL-17A, and IL-17F) were quantified by ELISA or CBA, and patients were assessed for clinical and exam’s variables. Simvastatin and atorvastatin at 50 μM promoted reduction in all cytokine levels with statistical significance, except for IL-6, which had its reduction only induced by the use of simvastatin. Statins, particularly simvastatin, appear to have an immunosuppressive effect in reducing all cytokine secretion levels from PBMCs of SSc in a dose-dependent manner.
Key Wordsscleroderma simvastatin atorvastatin Th cells
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
The study protocol was approved by the ethics committee of Universidade Federal de Pernambuco (CAAE: 63515916.1.0000.5208), according to the principles of the Declaration of Helsinki, and informed consent was obtained from all subjects.
- 3.Trifari, S., C.D. Kaplan, E.H. Tran, N.K. Crellin, and H. Spits. 2009. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nature Immunology 10 (8): 864–871. https://doi.org/10.1038/ni.1770.CrossRefPubMedGoogle Scholar
- 4.Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Research & Therapy. 2004;6(2):R120–R128. doi: https://doi.org/10.1186/ar1038.CrossRefGoogle Scholar
- 5.Murata, M., M. Fujimoto, T. Matsushita, Y. Hamaguchi, M. Hasegawa, K. Takehara, K. Komura, and S. Sato. 2008. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? Journal of Dermatological Science. 50 (3): 240–242. https://doi.org/10.1016/j.jdermsci.2008.01.001.CrossRefPubMedGoogle Scholar
- 6.Rossi, M., L. Bazzichi, L. Ghiadoni, I. Mencaroni, F. Franzoni, and S. Bombardieri. 2012. Increased finger skin vasoreactivity and stimulated vasomotion associated with simvastatin therapy in systemic sclerosis hypercholesterolemic patients. Rheumatology International 32 (12): 3715–3721. https://doi.org/10.1007/s00296-011-2183-5.CrossRefPubMedGoogle Scholar
- 10.Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis and Rheumatism 1980;23(5):581–590.Google Scholar
- 14.Cherfan, P., A. Tompa, A. Wikby, S. Lofgren, and L. Jonasson. 2007. Effects of simvastatin on human T cells in vivo. Atherosclerosis 193 (1): 186–192. https://doi.org/10.1016/j.atherosclerosis.2006.06.022.CrossRefPubMedGoogle Scholar
- 15.Blaschke, S., V. Viereck, G. Schwarz, H.M. Klinger, S. Guerluek, and G.A. Muller. 2009. Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scandinavian Journal of Rheumatology. 38 (4): 235–239. https://doi.org/10.1080/03009740802572475.CrossRefPubMedGoogle Scholar